Figure 3.
Nanoparticles loaded with cancer antigens and danger signals can target DCs in peripheral tissue via passive phagocytosis or active DC targeting with specific antibodies. Following nanoparticle uptake and processing, DCs become mature, present antigens on their surface, and migrate to LNs to activate T cells.